2165 related articles for article (PubMed ID: 8242661)
21. Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-gamma in oral cancer patients.
Yoneda K; Yamamoto T; Ueta E; Osaki T
J Clin Immunol; 1992 Jul; 12(4):289-99. PubMed ID: 1512302
[TBL] [Abstract][Full Text] [Related]
22. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
23. Phenotypic and cell cycle analysis of human peripheral blood mononuclear cells activated with interleukin-2 and/or OKT3.
Platts KE; Lawry J; Hancock BW; Rees RC
Exp Cell Res; 1993 Sep; 208(1):154-60. PubMed ID: 8359215
[TBL] [Abstract][Full Text] [Related]
24. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of superior anti-tumor cytotoxic response of interleukin 15-induced lymphokine-activated killer cells.
Ozdemir O; Ravindranath Y; Savaşan S
J Immunother; 2005; 28(1):44-52. PubMed ID: 15614044
[TBL] [Abstract][Full Text] [Related]
26. Isolation of human NK cells and generation of LAK activity.
Whiteside TL
Curr Protoc Immunol; 2001 May; Chapter 7():Unit 7.7. PubMed ID: 18432847
[TBL] [Abstract][Full Text] [Related]
27. Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
Bellone G; Novarino A; Vizio B; Brondino G; Addeo A; Prati A; Giacobino A; Campra D; Fronda GR; Ciuffreda L
Int J Oncol; 2009 Jun; 34(6):1701-15. PubMed ID: 19424589
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma.
Ron IG; Mordish Y; Eisenthal A; Skornick Y; Inbar MJ; Chaitchik S
Cancer Immunol Immunother; 1994 Jun; 38(6):379-84. PubMed ID: 8205559
[TBL] [Abstract][Full Text] [Related]
29. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
[TBL] [Abstract][Full Text] [Related]
30. Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study.
Belli F; Arienti F; Rivoltini L; Santinami M; Mascheroni L; Prada A; Ammatuna M; Marchesi E; Parmiani G; Cascinelli N
Melanoma Res; 1992 Nov; 2(4):263-71. PubMed ID: 1490114
[TBL] [Abstract][Full Text] [Related]
31. Interferon-gamma (IFN-gamma) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity--IFN-gamma-induced suppressive activity.
Toledano M; Mathiot C; Michon J; Andreu G; Lando D; Brandely M; Fridman WH
Cancer Immunol Immunother; 1989; 30(1):57-64. PubMed ID: 2513112
[TBL] [Abstract][Full Text] [Related]
32. Lymphokine-activated killer cytotoxicity and lymphocyte subpopulations in patients with acute leukemia.
Parrado A; Casares S; Rodríguez-Fernández JM
Leuk Res; 1994 Nov; 18(11):815-22. PubMed ID: 7526078
[TBL] [Abstract][Full Text] [Related]
33. Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results.
Buzaid AC; Grimm EA; Ali-Osman F; Ring S; Eton O; Papadopoulos NE; Bedikian A; Plager C; Legha SS; Benjamin R
Melanoma Res; 1994 Oct; 4(5):327-30. PubMed ID: 7858418
[TBL] [Abstract][Full Text] [Related]
34. Secondary cytokine production by lymphoid cells used in cellular immunotherapy.
Schoof DD; Hunt P; Obando JA; Cusack JC; Andrews V; Terashima Y; Eberlein TJ
Surg Oncol; 1992 Apr; 1(2):163-72. PubMed ID: 1341247
[TBL] [Abstract][Full Text] [Related]
35. Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion.
Takahashi K; Sone S; Saito S; Kamamura Y; Uyama T; Ogura T; Monden Y
Jpn J Cancer Res; 1995 Sep; 86(9):861-6. PubMed ID: 7591964
[TBL] [Abstract][Full Text] [Related]
36. DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma.
Buzaid AC; Ali-Osman F; Akande N; Grimm EA; Lee JJ; Bedikian A; Eton O; Papadopoulos N; Plager C; Legha SS; Benjamin RS
Melanoma Res; 1998 Apr; 8(2):145-8. PubMed ID: 9610867
[TBL] [Abstract][Full Text] [Related]
37. Laboratory correlates of chemoimmunotherapy with low-dose recombinant interleukin-2 and mitomycin C in patients with advanced carcinoma.
Arinaga S; Karimine N; Takamuku K; Nanbara S; Inoue H; Abe R; Watanabe D; Asoh T; Ueo H; Akiyoshi T
Cancer Invest; 1994; 12(6):588-96. PubMed ID: 7994593
[TBL] [Abstract][Full Text] [Related]
38. Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha-2b and IL-2.
Moltó L; Carballido J; Manzano L; Martinez-Martin B; Esquivel F; Chafer J; Olivier C; Alvarez-Mon M
J Immunother; 1999 May; 22(3):260-7. PubMed ID: 10335486
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-2. The experience of the Rotterdam Cancer Institute; Daniel den Hoed Kliniek.
Stoter G; Goey SH; Eggermont AM; Slingerland R; Braakman E; Lamers C; Bolhuis RL
Biotherapy; 1990; 2(3):261-5. PubMed ID: 2144993
[TBL] [Abstract][Full Text] [Related]
40. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]